Epidemiological evidence suggests an association between pre-eclampsia and low dietary calcium. Calcium supplementation in the second half of pregnancy reduces the severe consequences of pre-eclampsia with a trend to reduced deaths as well, but does not reduce pre-eclampsia to the extent expected from the epidemiological data.
The purpose of the Calcium and Pre-eclampsia study is to determine whether calcium supplementation before and in early pregnancy, including the time period when the placental origins of pre-eclampsia are thought to evolve, reduces pre-eclampsia.
Women with a history of pre-eclampsia in their most recent pregnancy who agree to participate receive calcium 500mg daily or placebo from enrolment until they become pregnant, and up to 20 weeks of pregnancy. After 20 weeks all women receive calcium supplementation with 1500mg daily according to WHO guidelines. The primary outcome is pre-eclampsia. About 1350 women will be enrolled to achieve the sample size of 540 women contributing data to the primary outcome.
The goal of this South African, Zimbabwean, and Argentinian RCT (in centres with known dietary calcium deficiency) to determine the effect of calcium supplementation before, and in the first half of, pregnancy on hypertension and other pregnancy outcomes.
Calcium supplementation commenced before pregnancy will reduce the incidence of pre-eclampsia more effectively than does supplementation starting at 20 weeks’ gestation.
Randomised, double-blind placebo-controlled clinical trial.
Women aged 18 to 45 years with a history of pre-eclampsia or eclampsia who plan to become pregnant.
- Age <18 years or >45 years
- Chronic hypertension
- Already pregnant
- Taking calcium supplementation
- History or symptoms of urolithiasis, renal disease, or parathyroid disease
- Not in a sexual relationship
- Using long-term contraception (eg hormonal, IUD, sterilization)
- No informed consent.
The study group will receive calcium supplementation with 500 mg elemental calcium daily from enrolment (before pregnancy) until 20 weeks' gestation.The control group will receive an identical placebo for the same duration. All women will receive unblinded calcium supplementation at 1000 mg from 20 weeks' gestation until delivery.
The primary outcome is Pre-eclampsia (diastolic blood pressure >90 mmHg on two occasions 4 hours apart, or >110 mmHg once, or systolic blood pressure >140 mmHg on two occasions 4 hours apart, or >160 mmHg once, after 20 weeks gestation in combination with proteinuria 2+ or more on urine dipstick, or >300mg/24 hours, or >500mg/L or urinary protein/creatinine ratio >0.034g/mmol, after 20 weeks' gestation).
Secondary outcomes related to concordance, maternal and neonatal well-being, and mode of delivery will be reported.
To show a reduction in pre-eclampsia from 25% to 15% (with alpha-5%, beta=80%) will require 540 participants.
Analysis will be by intention-to-treat. The results will be reported according to CONSORT guidelines. Categorical data will be presented as risk ratios with 95% confidence intervals. Continuous data will be presented as mean differences with 95% confidence intervals.
- The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia
- The effect of calcium supplementation on conception
- The effect of calcium supplementation on miscarriage
- The effect of calcium supplementation on urinary calcium creatinine ratio during pregnancy
- Pre-eclampsia biomarker study
- The relationship between inter-pregnancy interval and outcomes in the subsequent pregnancy: Systematic Review
- The relationship between inter-pregnancy interval and outcomes in the subsequent pregnancy: prospective study
- Calcium intake assessment of CAP trial participants
Since February 2017, we have discontinued participation of non-pregnant women in the study. We expect to achieve our target of 540 pregnancies beyond 24 weeks.
- Hofmeyr GJ. Prevention of pre-eclampsia: calcium supplementation and other strategies. Obstetrics and Gynaecology Forum. 2016 Jan 1; 26 (3):11-15.
- Cormick G, Betrán AP, Ciapponi A, Hall DR, Hofmeyr GJ; Calcium and Pre-eclampsia Study Group. Interpregnancy interval and risk of recurrent preeclampsia: systematic review and meta-analysis. Reprod Health. 2016 Jul 18;13(1):83.
- Hofmeyr GJ, Seuc A, Betrán AP, Purnat T, Ciganda A, Manyame S, Munjanja SP, Singata M, Fawcus S, Frank K Hall DR, Cormick G, Roberts J, Bergel E, Drebit S, von Dadelszen P, Belizan J on behalf of the calcium and Pre-eclampsia Study Group.The effect of calcium supplementation on blood pressure in non-pregnant women with previous preeclampsia: an exploratory, randomized placebo controlled study (WHO Study A65750). Pregnancy Hypertens. 2015 Oct;5(4):273–9.
- Cormick G, Ciapponi A, Cafferata ML, Belizan J. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015 Jun 30;6.
- Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014 Jan 1;6(6).
- Hofmeyr GJ, Belizan JM, Dadelszen P. Low‐dose calcium supplementation for preventing preeclampsia: a systematic review and commentary. BJOG. 2014 Jul 1;121(8):951–7.
- Seuc AH, Peregoudov A, Betran AP, Gulmezoglu AM. Intermediate outcomes in randomized clinical trials: An introduction. Trials. 2013 Mar 19;14(1):1.
- Hofmeyr GJ, Novikova N, Singata M, Fawcus S, Oyebajo A, Munjanja S, Belizán JM. Protocol 11PRT/4028: Long term calcium supplementation in women at high risk of pre-eclampsia: a randomised, placebo-controlled trial.